Search

Displaying results 1 - 10 of 12 in total
DrugBest match

Eculizumab

go.drugbank.com/drugs/DB01257
ApprovedInvestigational

Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Produ...

  1. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [eculizumab], [ravulizumab]) which are effective in mitigating complement-mediated intravascular hemolysis and thromboembolism.

  2. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration.

  3. Indication

    Thrombotic Microangiopathies

    go.drugbank.com/conditions/DBCOND0072350
    Drugs: Eculizumab · Ravulizumab
  4. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody [eculizumab]. … [A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization.

  5. Indication

    Neuromyelitis Optica Spectrum Disorders

    go.drugbank.com/conditions/DBCOND0067761
    Drugs: Eculizumab · Inebilizumab · Ravulizumab · Satralizumab
  6. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    Thrombotic microangiopathies (TMA), including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, are associated with injury and dysregulation of microvascular endothelium and platelets. Evidence increasingly poin...

  7. Indication

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    go.drugbank.com/conditions/DBCOND0028737
    Drugs: Crovalimab · Eculizumab · Iptacopan · Pegcetacoplan · Ravulizumab
  8. Drug

    Nomacopan

    go.drugbank.com/drugs/DB14991
    Investigational

    Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

  9. Indication

    Generalized Myasthenia Gravis

    go.drugbank.com/conditions/DBCOND0037937
    Drugs: Eculizumab · Efgartigimod alfa · Hyaluronidase (human recombinant) · Inebilizumab · Nipocalimab · Ravulizumab +2 more